Outset Medical Inc

NASDAQ:OMUnited States

Yesterday

Show headlines and story abstract

• -- Earnings Flash (OM) OUTSET MEDICAL Reports Q1 Revenue $28.2M, vs. Street Est of $30.3M, from 4:04PM ET on Wednesday May 08, 2024 by MT Newswires

  4:04PM ET on Wednesday May 08, 2024 by MT Newswires
  Companies Mentioned: OM
  04:04 PM EDT, 05/08/2024 (MT Newswires) -- ...

• Outset Medical Reports First Quarter 2024 Financial Results, from 4:02PM ET on Wednesday May 08, 2024 by Business Wire

  4:02PM ET on Wednesday May 08, 2024 by Business Wire
  Companies Mentioned: OM

  Outset Medical, Inc. (Nasdaq: OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2024.

• *DJ Outset Medical 1Q Loss/Shr 78c >OM, from 4:02PM ET on Wednesday May 08, 2024 by Dow Jones

  4:02PM ET on Wednesday May 08, 2024 by Dow Jones
  Companies Mentioned: OM
  =========== ========== (1) The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed balance sheets that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands): March 31, -------------------------------------- 2024 2023 ------------------- ----------------- Cash and cash equivalents $ 32,176 $ 36,386 Restricted cash 3,329 3,311 ----------- ---------- Total cash, cash equivalents and restricted cash(*) $ 35,505 $ 39,697 =========== ========== * The total cash, including restricted cash, cash equivalents and investment securities as of March 31, 2024 was $230.2 million; compared to $252.5 million as of March 31, 2023. Appendix A Outset Medical, Inc. Results of Operations -- Non-GAAP (in thousands, except per share amounts) (unaudited) Reconciliation between GAAP and non-GAAP net loss per share: Three Months Ended March 31, -------------------------- 2024 2023 ------------ ------------ GAAP net loss per share, diluted $ (0.78) $ (0.90) Stock-based compensation expense 0.16 0.18 Severance and related charges, net 0.05 -- ------- ------- Non-GAAP net loss per share, diluted $ (0.57) $ (0.72) ======= ======= Reconciliation between GAAP and non-GAAP net loss: Three Months Ended March 31, -------------------------- 2024 2023 ------------ ------------ GAAP net loss, diluted $(39,944) $(43,971) Stock-based compensation expense 8,203 8,538 Severance and related charges, net 2,473 -- ------- ------- Non-GAAP net loss, diluted $(29,268) $(35,433) ======= ======= Reconciliation between GAAP and non-GAAP results of operations: Three Months Ended March 31, -------------------------- 2024 2023 ------------ ------------ GAAP gross profit $ 8,215 $ 6,428 Stock-based compensation expense 265 358 Severance and related charges, net 279 -- ------- ------- Non-GAAP gross profit $ 8,759 $ 6,786 ======= ======= GAAP gross margin 29.2% 19.2% Stock-based compensation expense 0.9 1.1 Severance and related charges, net 1.0 -- ------- ------- Non-GAAP gross margin 31.1% 20.3% ======= ======= GAAP research and development expense $ 12,635 $ 13,793 Stock-based compensation expense (2,332) (2,615) Severance and related charges, net (990) -- ------- ------- Non-GAAP research and development expense $ 9,313 $ 11,178 ======= ======= GAAP sales and marketing expense $ 21,048 $ 24,333 Stock-based compensation expense (1,459) (2,598) Severance and related charges, net (793) -- ------- ------- Non-GAAP sales and marketing expense $ 18,796 $ 21,735 ======= ======= GAAP general and administrative expense $ 11,444 $ 11,787 Stock-based compensation expense (4,147) (2,967) Severance and related charges, net (411) -- ------- ------- Non-GAAP general and administrative expense $ 6,886 $ 8,820 ======= ======= GAAP total operating expense $ 45,127 $ 49,913 Stock-based compensation expense (7,938) (8,180) Severance and related charges, net (2,194) -- ------- ------- Non-GAAP total operating expense $ 34,995 $ 41,733 ======= =======
  

• Outset Medical Reports First Quarter 2024 Financial Results, from 4:02PM ET on Wednesday May 08, 2024 by Dow Jones

  4:02PM ET on Wednesday May 08, 2024 by Dow Jones
  Companies Mentioned: OM
  =========== ========== (1) The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed balance sheets that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands): March 31, -------------------------------------- 2024 2023 ------------------- ----------------- Cash and cash equivalents $ 32,176 $ 36,386 Restricted cash 3,329 3,311 ----------- ---------- Total cash, cash equivalents and restricted cash(*) $ 35,505 $ 39,697 =========== ========== * The total cash, including restricted cash, cash equivalents and investment securities as of March 31, 2024 was $230.2 million; compared to $252.5 million as of March 31, 2023. Appendix A Outset Medical, Inc. Results of Operations -- Non-GAAP (in thousands, except per share amounts) (unaudited) Reconciliation between GAAP and non-GAAP net loss per share: Three Months Ended March 31, -------------------------- 2024 2023 ------------ ------------ GAAP net loss per share, diluted $ (0.78) $ (0.90) Stock-based compensation expense 0.16 0.18 Severance and related charges, net 0.05 -- ------- ------- Non-GAAP net loss per share, diluted $ (0.57) $ (0.72) ======= ======= Reconciliation between GAAP and non-GAAP net loss: Three Months Ended March 31, -------------------------- 2024 2023 ------------ ------------ GAAP net loss, diluted $(39,944) $(43,971) Stock-based compensation expense 8,203 8,538 Severance and related charges, net 2,473 -- ------- ------- Non-GAAP net loss, diluted $(29,268) $(35,433) ======= ======= Reconciliation between GAAP and non-GAAP results of operations: Three Months Ended March 31, -------------------------- 2024 2023 ------------ ------------ GAAP gross profit $ 8,215 $ 6,428 Stock-based compensation expense 265 358 Severance and related charges, net 279 -- ------- ------- Non-GAAP gross profit $ 8,759 $ 6,786 ======= ======= GAAP gross margin 29.2% 19.2% Stock-based compensation expense 0.9 1.1 Severance and related charges, net 1.0 -- ------- ------- Non-GAAP gross margin 31.1% 20.3% ======= ======= GAAP research and development expense $ 12,635 $ 13,793 Stock-based compensation expense (2,332) (2,615) Severance and related charges, net (990) -- ------- ------- Non-GAAP research and development expense $ 9,313 $ 11,178 ======= ======= GAAP sales and marketing expense $ 21,048 $ 24,333 Stock-based compensation expense (1,459) (2,598) Severance and related charges, net (793) -- ------- ------- Non-GAAP sales and marketing expense $ 18,796 $ 21,735 ======= ======= GAAP general and administrative expense $ 11,444 $ 11,787 Stock-based compensation expense (4,147) (2,967) Severance and related charges, net (411) -- ------- ------- Non-GAAP general and administrative expense $ 6,886 $ 8,820 ======= ======= GAAP total operating expense $ 45,127 $ 49,913 Stock-based compensation expense (7,938) (8,180) Severance and related charges, net (2,194) -- ------- ------- Non-GAAP total operating expense $ 34,995 $ 41,733 ======= =======